Recent News
-
Aspira Women’s Health, Inc. to Host Key Opinion Leader Call on Ovarian Cancer Diagnostics, Innovation Pipeline, and Rebranding Initiatives
For a pdf of this press release please click here AUSTIN, Texas — September 15, 2020 — Aspira Women’s Health, Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced that it will host a key opinion leader (KOL) call on ovarian cancer diagnostics, innovation pipeline, and rebranding initiatives on Friday, September 25, 2020 at 12:00pm…
-
Aspira Women’s Health, Inc., to Present at Cantor Virtual Healthcare Conference
For a pdf of this press release please click here AUSTIN, Texas — September 8, 2020 — Aspira Women’s Health Inc. (“ASPIRA”) (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced management will participate in the 2020 Cantor Virtual Healthcare Conference taking place on September 15-17, 2020. Valerie Palmieri, President and Chief Executive Officer, and Robert…
-
Aspira Women’s Health Reports Second Quarter 2020 Financial Results
Conference Call scheduled for today, August 13th at 4:30 p.m. ET For a pdf of this press release including consolidated balance sheets please click here AUSTIN, Texas — August 13, 2020 — Aspira Women’s Health Inc. (“ASPIRA”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on gynecologic disease, today reported its financial results for the second…
-
Aspira Women’s Health CEO Valerie Palmieri quoted in Forbes
Valerie Palmieri, President and CEO of Aspira Women's Health, was quoted in an article on Forbes.com today, Wednesday, July 8, 2020. The article describes the gender gap which exists in healthcare today and the steps companies are taking to challenge the status quo through research, innovation, and disruptive technology. Read the full article here.
-
Aspira Women’s Health Inc. Announces Equity Financing of Approximately $11 Million
For a pdf of this press release please click here AUSTIN, Texas, July 1, 2020 — Aspira Women’s Health Inc. (Nasdaq: AWH) (“ASPIRA”), a bioanalytical-based women’s health company focused on gynecologic disease, today announced that investors, including certain affiliates of Jack W. Schuler, ASPIRA’s largest stockholder, have agreed to purchase approximately $11 million of unregistered shares…